Cargando…
Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
Angiopoietin-like protein 3 (ANGPTL3) is an important regulator of lipoproteins by inhibiting both lipoprotein and endothelial lipases. It has been intensively investigated as a drug target for the treatment of dyslipidemia. In the present study, a modified small interfering RNA (siRNA) conjugated w...
Autores principales: | Wang, Jue, Zheng, Wen, Zheng, Shuquan, Yuan, Ye, Wen, Wei, Cui, Weiyi, Xue, Lifang, Sun, Xueting, Shang, Haibao, Zhang, Hongyan, Xiao, Rui-Ping, Gao, Shan, Zhang, Xiuqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804015/ https://www.ncbi.nlm.nih.gov/pubmed/36618267 http://dx.doi.org/10.1016/j.omtn.2022.11.023 |
Ejemplares similares
-
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020) -
Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011) -
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018) -
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017) -
GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics
por: Thangamani, Lokesh, et al.
Publicado: (2021)